No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
Politou
Marianna
M
Karadimitris
Anastasios
A
Terpos
Evangelos
E
Kotsianidis
Ioannis
I
Apperley
Jane F
JF
Rahemtulla
Amin
A
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004351:Drug Resistance; D005260:Female; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D011480:Protease Inhibitors / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000235:genetics*; D011719:Pyrazines / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; C088874:PSMB5 protein, human; D046988:Proteasome Endopeptidase Complex